The 13-Valent Pneumococcal Conjugate Vaccine Elicits Serological Response and Lasting Protection in Selected Patients With Primary Humoral Immunodeficiency

The 13-Valent Pneumococcal Conjugate Vaccine Elicits Serological Response and Lasting Protection in Selected Patients With Primary Humoral Immunodeficiency

BackgroundPatients with primary humoral immunodeficiency are more prone to invasive as well as recurrent pneumococcal infections. Therefore, anti-pneumococcal vaccination including the 13-valent conjugate vaccine is recommended. Nevertheless, to date, no data is available on immunogenicity of this v...

Full description

Bibliographic Details
Main Authors: Ailsa Robbins, Mathilde Bahuaud, Maxime Hentzien, Quentin Maestraggi, Coralie Barbe, Delphine Giusti, Richard Le Naour, Frederic Batteux, Amélie Servettaz
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Immunology
Subjects:
primary humoral immunodeficiency
common variable immunodeficiency
IgG subclass deficiency
pneumococcal vaccine
conjugate vaccination
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.697128/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.697128/full

Similar Items